Advancing the Development of National Childhood Cancer Care Strategies in Latin America
Conclusion The fruits of this deliberative process include novel policy-relevant research and advocacy endeavours, and enhanced relationships among diverse regional stakeholders to support evidence and policy development relevant to childhood cancer care in Latin America. Deliberative dialogues hold promise for advancing evidence-informed health system strategies on childhood cancer care in other LMIC contexts. (Source: Journal of Cancer Policy)
Source: Journal of Cancer Policy - December 14, 2016 Category: Cancer & Oncology Source Type: research
Epidemiological hazards of tobacco and its manifestations in oral health of a screened population in Northern India.
Conclusion Findings of study indicate that tobacco addiction (single or joint) was found to be statistically significant with the oral mucosal lesions and trismus. Risk of tobacco consumption in either form was present in all age groups, which is significantly contributing to increase odds of trismus and oral mucosal lesions especially in younger and middle aged population. (Source: Journal of Cancer Policy)
Source: Journal of Cancer Policy - December 14, 2016 Category: Cancer & Oncology Source Type: research
Evidence, value and hope — Allocating resources for cancer
Publication date: Available online 1 December 2016 Source:Journal of Cancer Policy (Source: Journal of Cancer Policy)
Source: Journal of Cancer Policy - December 11, 2016 Category: Cancer & Oncology Source Type: research
Assessing the value of cancer treatments from real world data —Issues, empirical examples and lessons learnt
Publication date: Available online 19 November 2016 Source:Journal of Cancer Policy Author(s): F. Moen, J. Svensson, K. Steen Carlsson There is an increasing demand for real world evidence. The shift towards relative effectiveness assessment increasingly based on real world data is a natural consequence of the shift towards new adaptive pathways for development and introduction of new medicines in cancer care. The increasing number of alternative treatment options will further increase the need for outcomes data to help optimize the clinical pathways and resource allocation. In this article the authors explore the opp...
Source: Journal of Cancer Policy - December 2, 2016 Category: Cancer & Oncology Source Type: research
Evidence, value and hope – allocating resources for cancer
Publication date: Available online 1 December 2016 Source:Journal of Cancer Policy (Source: Journal of Cancer Policy)
Source: Journal of Cancer Policy - December 1, 2016 Category: Cancer & Oncology Source Type: research
Assessing the value of cancer treatments from real world data − issues, empirical examples and lessons learnt
Publication date: Available online 19 November 2016 Source:Journal of Cancer Policy Author(s): F. Moen, J. Svensson, K.Carlsson Steen (Source: Journal of Cancer Policy)
Source: Journal of Cancer Policy - November 19, 2016 Category: Cancer & Oncology Source Type: research
Value and cancer medicines —A personal view
Publication date: Available online 5 November 2016 Source:Journal of Cancer Policy Author(s): Kenneth R Paterson This paper outline the attributes of new medicines that are perceived to offer added clinical value by those making decisions about pricing and reimbursement, often called ‘payers’. It also describes other attributes that, although they may represent some progress in cancer care, may not represent added value for which a payer would wish to pay, and some more controversial areas where there is some debate and difference of view on whether added value exists. A review of data from the Scottish Medicines Co...
Source: Journal of Cancer Policy - November 9, 2016 Category: Cancer & Oncology Source Type: research
VALUE AND CANCER MEDICINES − A Personal View
Publication date: Available online 5 November 2016 Source:Journal of Cancer Policy Author(s): Kenneth R Paterson This paper outline the attributes of new medicines that are perceived to offer added clinical value by those making decisions about pricing and reimbursement, often called ‘payers’. It also describes other attributes that, although they may represent some progress in cancer care, may not represent added value for which a payer would wish to pay, and some more controversial areas where there is some debate and difference of view on whether added value exists. A review of data from the Scottish Medicines Co...
Source: Journal of Cancer Policy - November 5, 2016 Category: Cancer & Oncology Source Type: research
Assessment of value for resource allocation in cancer care
Publication date: Available online 20 October 2016 Source:Journal of Cancer Policy Author(s): Peter Lindgren, Bengt Jönsson, Nils Wilking (Source: Journal of Cancer Policy)
Source: Journal of Cancer Policy - October 29, 2016 Category: Cancer & Oncology Source Type: research
Trends in Antineoplastic Receipt after Medicare Payment Reform: Implications for Future Oncology Payment Design
Conclusions Our results indicate that providers responded to reimbursement changes after the MMA by increasing use of newly approved agents, but the magnitude of the response was small and limited to individuals diagnosed with Stage IV disease. (Source: Journal of Cancer Policy)
Source: Journal of Cancer Policy - September 28, 2016 Category: Cancer & Oncology Source Type: research
Knowledge and acceptance of Human Papillomavirus (HPV) and HPV vaccination in adolescent boys worldwide: a systematic review.
Conclusions Comparison and synthesis of research concerning HPV knowledge and attitudes was made difficult due to the lack of universal definition of vaccine acceptance, and no universally accepted tool for its measurement or for the measurement of HPV knowledge. It is imperative that future research utilises consistent measures of HPV knowledge and attitudes to facilitate interpretation and comparison across studies internationally. Prospective longitudinal studies would be more informative providing data on factors that influenced the move from vaccine intention to uptake. (Source: Journal of Cancer Policy)
Source: Journal of Cancer Policy - September 26, 2016 Category: Cancer & Oncology Source Type: research
Rare cancers —Rarity as a cost and value argument
Publication date: Available online 9 September 2016 Source:Journal of Cancer Policy Author(s): J.-Matthias Graf von der Schulenburg, Frédéric Pauer Here is a paradox in medicine: rare diseases are unusual, but developing a rare disease is quite frequent. This is also true for rare forms of cancer. Almost every 20th person in the world suffers from a rare disease, and about one quarter of all new diagnosed cancers belong to rare cancers. The downside of rare diseases for patients is the difficulty to find the right institution for their treatment, for health care payers it is the costly treatments, and for medical pro...
Source: Journal of Cancer Policy - September 19, 2016 Category: Cancer & Oncology Source Type: research
QALYs as a Measure of Value in Cancer
Publication date: Available online 9 September 2016 Source:Journal of Cancer Policy Author(s): Nancy J Devlin, Paula K Lorgelly Quality adjusted life years (QALYs) offer a measure of value which is advantageous for health technology appraisal (HTA). As a composite measure, combining length of life and preference-based self-reported health related quality of life (HRQoL), the application of QALYs, and the assessment of value, in oncology and cancer care can be challenging. With respect to assessing the effectiveness of an intervention at reducing mortality, clinical trials in oncology predominantly focus on progression ...
Source: Journal of Cancer Policy - September 13, 2016 Category: Cancer & Oncology Source Type: research
Costs matter: The impact of disclosing treatment costs and provider profit on patients ’ decisions
Conclusion Patients expressed significantly less interest in four distinct cancer treatments after disclosure of out-of-pocket costs and provider profit. Discussions about these issues are desired in the clinical encounter. As the economic burden of cancer care shifts to patients, communication about costs and provider profit may be needed to ensure that patients are fully informed when making treatment decisions. (Source: Journal of Cancer Policy)
Source: Journal of Cancer Policy - September 13, 2016 Category: Cancer & Oncology Source Type: research
Ethics, priorities and cancer
Publication date: Available online 12 September 2016 Source:Journal of Cancer Policy Author(s): Anthony J Culyer Beginning with the ethical case for maximising the impact of health care resources on health, this article examines nine arguments for exempting cancer treatments from rigorous economic evaluation or for relaxing some of the conditions often required if an intervention is to be provided at public expense. Some of these may have validity under particular circumstances but, in general, if these arguments apply at all they apply also to other treatments for similarly placed patients (for example, those near the ...
Source: Journal of Cancer Policy - September 12, 2016 Category: Cancer & Oncology Source Type: research
